GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » E10

SYRS (Syros Pharmaceuticals) E10 : $-39.08 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Syros Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-39.08 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-14), Syros Pharmaceuticals's current stock price is $0.09. Syros Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was $-39.08. Syros Pharmaceuticals's Shiller PE Ratio of today is .


Syros Pharmaceuticals E10 Historical Data

The historical data trend for Syros Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals E10 Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -39.08

Competitive Comparison of Syros Pharmaceuticals's E10

For the Biotechnology subindustry, Syros Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Shiller PE Ratio falls into.



Syros Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syros Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.16/133.0289*133.0289
=-0.160

Current CPI (Sep. 2024) = 133.0289.

Syros Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201412 0.000 99.070 0.000
201503 -3.223 99.621 -4.304
201506 -28.698 100.684 -37.917
201509 -38.020 100.392 -50.380
201512 -46.739 99.792 -62.306
201603 -5.415 100.470 -7.170
201606 -54.200 101.688 -70.905
201609 -6.500 101.861 -8.489
201612 -4.690 101.863 -6.125
201703 -4.900 102.862 -6.337
201706 -5.200 103.349 -6.693
201709 -5.300 104.136 -6.771
201712 -5.800 104.011 -7.418
201803 -4.800 105.290 -6.065
201806 -4.300 106.317 -5.380
201809 -4.700 106.507 -5.870
201812 -5.400 105.998 -6.777
201903 -4.900 107.251 -6.078
201906 -4.700 108.070 -5.785
201909 -4.700 108.329 -5.772
201912 -4.600 108.420 -5.644
202003 -3.900 108.902 -4.764
202006 -3.800 108.767 -4.648
202009 -4.300 109.815 -5.209
202012 -6.300 109.897 -7.626
202103 -2.300 111.754 -2.738
202106 -3.600 114.631 -4.178
202109 -4.140 115.734 -4.759
202112 -3.780 117.630 -4.275
202203 -3.990 121.301 -4.376
202206 -5.400 125.017 -5.746
202209 -3.210 125.227 -3.410
202212 -0.236 125.222 -0.251
202303 -0.850 127.348 -0.888
202306 -1.300 128.729 -1.343
202309 -1.430 129.860 -1.465
202312 -2.220 129.419 -2.282
202403 -0.100 131.776 -0.101
202406 -0.590 132.554 -0.592
202409 -0.160 133.029 -0.160

Add all the adjusted EPS together and divide 10 will get our e10.


Syros Pharmaceuticals  (NAS:SYRS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Syros Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Executives
Nancy A Simonian director, 10 percent owner, officer: President & CEO C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk officer: Chief Legal Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421